tbuckley/cabot-search huggingface dataset:
Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes
Authors: R. Rouzier
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To determine the incidence and prognostic significance of eradication of cytologically proven axillary lymph node metastases in breast cancer patients treated with primary chemotherapy. PATIENTS AND METHODS: Between January 1985 and December 1994, 152 breast cancer patients with invasive T1 to T3 tumors and axillary metastases cytologically proven by fine-needle sampling underwent primary chemotherapy followed by lumpectomy or mastectomy, level I and II axillary lymph node dissection, and irradiation. We studied pathologic complete responses (pCRs) of axillary nodes and breast tumors, as well as predictors of distant metastases. RESULTS: Thirty-five patients (23%) had axillary pCRs, and 20 patients (13.2%) had pCRs of primary breast tumors. Scarff-Bloom-Richardson grade 3 tumors (P = .04) and a clinical response to chemotherapy ≥ 50% (P = .003) were associated with negative axillary status at dissection. An initial tumor size ≤ 3 cm (63 patients) was associated with pCR of the primary tumor (P = .02) but not with complete histologic clearance of axillary lymph nodes. The median length of follow-up was 75 months. In the univariate analysis, age greater than 40 years (P = .003), absence of residual nodal disease (P = .01), and pCR of the tumor (P = .05) were associated with better distant disease-free survival. Five-year distant disease-free survival rates were 73.5% ± 14.9% among patients with no involved nodes at the time of surgery and 48.7% ± 9.2% among patients with residual nodal disease. In the multivariate Cox regression analysis, parameters associated with poor distant disease-free survival were age ≤ 40 years (P = .002), persistence of nodal involvement (P = .03), and S-phase fraction greater than 4% (P = .02). CONCLUSION: Our results suggest that axillary status is a better prognostic factor than response of the primary tumor to primary chemotherapy.
Abstract 17527: Partitioning Echocardiographic Size and Function Parameters of the Right Ventricle Using CMR Normative Values from the MESA Study
Authors: Karima Addetia, Nadia El-Hangouche, Amit R Patel, Michael J Wilkinson, Roberto M Lang, Kirk T Spencer
Journal: Circulation (2014)

Introduction: Right ventricular (RV) size and function are important predictors of outcomes. There are, however, no cut-off values for degrees of RV enlargement or dysfunction. Recent guidelines on the right heart classify measurements only as abnormal or normal. In a cohort of patients with closely-spaced 2DE and cardiovascular magnetic resonance (CMR) we sought to determine magnitudes of abnormality in 2DE values by using CMR normative values as determined by the Multi-Ethnic Study of Atherosclerosis (MESA) study. Methods: We studied 217 patients, who had CMR (1.5T), and 2DE within 2±2.5 d. CMR RV ejection fraction (EF) and end-diastolic volume (EDV) were measured using the method of disks. The RV-focused apical 4-chamber view was used to measure the functional parameters, TAPSE (M-mode) and S’ (pulsed-wave Doppler), and fractional area change (FAC) as well as the size parameters of end-diastolic basal (RVEDDb) and mid (RVEDDm) diameters. Using CMR normal values from the MESA study for males and females separately, magnitudes of abnormality in RV enlargement and dysfunction were determined using SDs from the population mean. Patients were categorized based on CMR results. Values for corresponding 2DE size and function parameters were then calculated for each category using the regression line and cut-offs proposed. Results: Mean CMR and 2DE values are reported (Table 1). At least moderate correlations (r&gt;0.50) were seen between the functional parameters and CMR RV EF and size parameters and CMR RV EDV. The best correlation was seen between RV EDA and CMR RV EDV (r=0.79). Echocardiographic parameters at 0, 2, 4 and 6 SDs from MESA-derived normal values for males and females separately are shown (Tables 2&amp;3). Conclusions: Studies combining information from echocardiography and CMR performed in close proximity could enhance the ability to qualify RV size and function other than as normal or abnormal potentially providing more value to the clinician.
Journal of Pediatrics, St. Louis
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A new antidepressant of the tricyclic group: nortriptyline hydrochloride (aventyl hydrochloride)
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
General surgery
Authors: T Houghton, D Houghtont, P Redmondt, R Watson, R Watsont, D Bouchier- Hayes, G Cadiere, J Bruyns, J Himpens, J Houben, M Gelin, J Panzer
Journal: Gut (1993)

Immune impairment following surgical injury may be associated with deleterious septic sequelae.Psychoneuroimmunological researches have indicated the importance of psychological well-being to physical health in general and to immunological functioning in particular.Pre-and post-operative immunological and psychological status were compared in two groups of patients, randomised to open (N= 14) or laparoscopic (N= 16) cholecystectomy and matched for age, height, weight, ASA scores and operation time.Immune parameters including tumour necrosis factor (TNF) and neutrophil chemotaxis (PMN) were assessed pre-operatively and on post-operative day one.Psychological variables were also assessed pre-and post-operatively and included anxiety (state, trait, somatic and free-floating), social isolation, depression, health locus of control, attitudes towards self and others, life style, adjustment to hospital and patient reports of anticipated and experienced pain. Results6TNF oPMN (pg/ml) (units) study group: open 1.9+/-0.8173+/-54 closed 0.5+/-0.4*134+/-58* Open=open cholecystectomy closed=laparoscopic cholecystectomy Values expressed=mean+/-standard deviation * p= <0.05 versus open cholecystectomy Antic Exper Trait GHO(A) GHO(B) PAIN PAIN ANX Pre-op TNF 0.20 -2.17* 0.01 1.00 1.17 Post-op TNF 2.10* -0.58 1.86* 2.38* 1.95* Pre-op NC 0.49 1.99* 1.01 0.60 2.27* Post-op NC 0.55 0.13 2.31* 1.67 0.51 GHQ(A)=somatic anxiety.GHQ(B)=free-floating anxiety.Antic pain=anticipated pain.Exper pain=experienced pain.Z scores corrected for ties.* p= sO.05These results show significant alterations in TNF and PMN in open versus laparoscopic study groups.Statistically significant relationships were found between the psychological and immunological variables.For example, free-floating anxiety and patients' anticipa- tions and experience of pain correlated respectively with pre-and post-operative levels of TNF and neutrophil chemotaxis.This study has revealed significant differences in immunological and psychological reactions in patients undergoing open and laparoscopic cholecystectomy.The inter- relationship found between aspects of immunological and psychological functioning needs further investigation, to determine its significance in surgical outcomes.
Guidelines for the management of convulsions with fever. Joint Working Group of the Research Unit of the Royal College of Physicians and the British Paediatric Association.
Authors: A Hopkins, Martin Dennis, Charles Warlow
Journal: BMJ (1991)

are currently so preoccupied with the funding impli- cations of change.But rejoicing may yet be premature, for the spectre of a higher prevalence of factor VIII inhibitors in patients receiving high potency concen- trates needs to be looked at and, we hope, dispelled.I Cash JD.Coagulation factor VIII concentrates and the marketplace.
PHYSICIANS AND THE NRA
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A MORPHOLOGIC BASIS FOR TISSUE RESISTANCE
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sick kids find help in a Cyberspace world
Authors: J. Stephenson
Journal: JAMA (1995)

YOUNGSTERS at four hospitals scattered across the country recently "met" with a movie mogul and a four-star general to roam a computer-generated world of tropical rain forests, caves with hidden passages, and other inviting destinations— a virtual playground that its developers hope will diminish the pain, anxieties, and isolation of children hospitalized due to serious and chronic illness. The occasion was a demonstration of the multimillion-dollar Starbright World network, during which young patients at Mount Sinai Medical Center in New York, NY, visited with movie director Steven Spielberg, General H. Norman Schwarzkopf (ret), and children from three other hospitals participating in the linkup. Spielberg, director of such films as "Jurassic Park," "Schindler's List," and "E.T. The Extraterrestrial," heads the foundation that is creating and financing the multimedia network. Schwarzkopf is leading the nationwide capital campaign to finance it. Mount Sinai and the other three hospitals participating in the network— Children's
Association News
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bioethics Commission examines informed consent from subjects who are 'decisionally incapable'
Authors: C. Marwick
Journal: JAMA (1997)

THE NATIONAL Bioethics Advisory Commission has turned its attention from an administration-mandated consideration of cloning to one of the major issues it was created to examine—the further steps needed to better protect human subjects who participate in medical research. The commission is addressing the issue of obtaining informed consent from "decisionally incapable" subjects, in the phrase used by the chair of its human subjects subcommittee, James F. Childress, PhD, Kyle Professor of Religious Studies at the University of Virginia, Charlottesville. While federal regulations have been in force for a number of years to ensure that properly informed consent is obtained from human research subjects or their legally authorized surrogates, these regulations do not address the competence of research subjects to decide to participate in studies. Some research, especially in the area of neurobiology, involves subjects who may be cognitively impaired to some degree. At the subcommittee's meeting in July, the
Correction: Novel evidence that extracellular nucleotides and purinergic signaling induce innate immunity-mediated mobilization of hematopoietic stem/progenitor cells
Authors: Mateusz Adamiak, Kamila Bujko, Monika Cymer, Monika Plonka, Talita Glaser, Magda Kucia, Janina Ratajczak, Henning Ulrich, Ahmed Abdel-Latif, Mariusz Z. Ratajczak
Journal: Leukemia (2019)

Following the publication of this article, the authors noted that the following should be included in the Acknowledgements section: "MA is the recipient of a START scholarship (0785) from FNP". The authors wish to apologise for any inconvenience caused.
NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with <sup>177</sup>Lu-DOTATATE.
Authors: Jonathan R. Strosberg, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David L Bushnell, Martyn E. Caplin, Richard P. Baum, Timothy J. Hobday, Andrew Eugene Hendifar, Kjell E. Oberg, Maribel Lopera Sierra, Dik J. Kwekkeboom, Philippe B. Ruszniewski, Eric Krenning, Pamela L. Kunz
Journal: Journal of Clinical Oncology (2016)

4005 Background: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy. The purpose of this phase III trial was to evaluate the efficacy and safety of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) in patients with advanced, progressive sstr positive midgut NETs. Methods: 230 patients with grade 1-2 metastatic midgut NETs were randomized to Lutathera, 7.4 GBq every 8 weeks (x 4 administrations) vs Octreotide LAR 60 mg every 4 weeks. Primary endpoint was PFS (RECIST 1.1) with tumor assessment every 12 weeks. Secondary objectives included ORR, OS, toxicity and QoL. Results: In the intent-to-treat population (ITT), the median PFS was not reached for Lutathera and was 8.4 months with control (p < 0.0001, HR 0.21). There were 23 centrally confirmed disease progressions or deaths in the Lutathera arm and 67 in the Octreotide LAR 60 mg arm. The objective radiographic response rate (ORR) was 18% with Lutathera and 3% with control (p = 0.0008). Besides the scintigraphic 111In-pentetreotide tumor uptake score (Krenning scale > = 2), tumor burden and Ki67 grade had no significant effect on clinical efficacy outcomes (PFS, OS, TTP) in the Cox regression models. Interim OS analysis (13 deaths in Lutathera group and 22 in control group; p = 0.019) strongly suggests an improvement in OS. Only 5% (6 patients) experienced dose modifying toxicity with Lutathera. Grade 3 or 4 adverse events of neutropenia, thrombocytopenia and lymphopenia occurred in 1%, 2% and 9% of patients in Lutathera arm vs. none in controls. Conclusions: The NETTER-1 trial provides evidence for a clinically meaningful and statistically significant increase in PFS and ORR, and suggests a potential survival benefit in patients with advanced midgut NETs treated with Lutathera in both ITT and PP analyses. Lutathera safety profile was found to be very favorable. Clinical trial information: NCT01578239.
Compliance as a determinant of serum digoxin concentration
Authors: M. Weintraub
Journal: JAMA (1973)

Serum digoxin concentrations were measured in 101 outpatients by radioimmunoassay with radioactive iodine 125 to evaluate factors affecting these concentrations. Patient compliance, ascertained by asking how often patients missed taking digoxin, was the most important determinant of serum digoxin concentrations. "Compliant" patients had mean serum digoxin concentrations (±SD) of 1.2±0.8 ng—l; "noncompliant" patients had a mean of 0.7±0.7 ng/ml(P (<i>P</i>&lt;.001). Factors affecting patient compliance were also investigated. Of patients not taking diuretics, 82% were compliant whereas 60% of patients taking both digoxin and diuretics were compliant (<i>P</i>&lt;.01). Analysis of relationships between serum concentration of digoxin and renal function, age, and dosage in outpatients should include compliance as a variable. Physicians should find out if patients are adhering to the prescribed regimen and search for correctable causes of noncompliance.
Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma
Authors: Gulab S. Zode, Markus H. Kuehn, Darryl Y. Nishimura, Charles C. Searby, Kabhilan Mohan, Sinisa D. Grozdanic, Kevin Bugge, Michael G. Anderson, Abbot F. Clark, Edwin M. Stone, Val C. Sheffield
Journal: Journal of Clinical Investigation (2011)

Mutations in myocilin (MYOC) are the most common genetic cause of primary open angle glaucoma (POAG), but the mechanisms underlying MYOC-associated glaucoma are not fully understood. Here, we report the development of a transgenic mouse model of POAG caused by the Y437H MYOC mutation; the mice are referred to herein as Tg-MYOCY437H mice. Analysis of adult Tg-MYOCY437H mice, which we showed express human MYOC containing the Y437H mutation within relevant eye tissues, revealed that they display glaucoma phenotypes (i.e., elevated intraocular pressure [IOP], retinal ganglion cell death, and axonal degeneration) closely resembling those seen in patients with POAG caused by the Y437H MYOC mutation. Mutant myocilin was not secreted into the aqueous humor but accumulated in the ER of the trabecular meshwork (TM), thereby inducing ER stress in the TM of Tg-MYOCY437H mice. Furthermore, chronic and persistent ER stress was found to be associated with TM cell death and elevation of IOP in Tg-MYOCY437H mice. Reduction of ER stress with a chemical chaperone, phenylbutyric acid (PBA), prevented glaucoma phenotypes in Tg-MYOCY437H mice by promoting the secretion of mutant myocilin in the aqueous humor and by decreasing intracellular accumulation of myocilin in the ER, thus preventing TM cell death. These results demonstrate that ER stress is linked to the pathogenesis of POAG and may be a target for treatment in human patients.
Beiträge zur Kenntnis der Genese der Ovarialembryome. Experimentelle Untersuchungen über parthenogenetische Overialgravidität bei Amphibien.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal